Cite
MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC
MLA
Logan C. Tyler, et al. “MET Gene Amplification Is a Mechanism of Resistance to Entrectinib in ROS1+ NSCLC.” Thoracic Cancer, vol. 13, no. 21, Nov. 2022, pp. 3032–41. EBSCOhost, https://doi.org/10.1111/1759-7714.14656.
APA
Logan C. Tyler, Anh T. Le, Nan Chen, Hala Nijmeh, Liming Bao, Timothy R. Wilson, David Chen, Brian Simmons, Kristen M. Turner, Dean Perusse, Shailaja Kasibhatla, Jason Christiansen, Arkadiusz Z. Dudek, & Robert C. Doebele. (2022). MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC. Thoracic Cancer, 13(21), 3032–3041. https://doi.org/10.1111/1759-7714.14656
Chicago
Logan C. Tyler, Anh T. Le, Nan Chen, Hala Nijmeh, Liming Bao, Timothy R. Wilson, David Chen, et al. 2022. “MET Gene Amplification Is a Mechanism of Resistance to Entrectinib in ROS1+ NSCLC.” Thoracic Cancer 13 (21): 3032–41. doi:10.1111/1759-7714.14656.